Literature DB >> 7986726

Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A.

E M Duncan1, B M Duncan, L J Tunbridge, J V Lloyd.   

Abstract

A higher result for plasma factor VIII:C measured by the one-stage as compared with the two-stage method has been described in some patients with haemophilia A or with von Willebrand's disorder. We used both methods to measure FVIII:C in 95 patients with haemophilia A. The results were equivalent in all 21 patients with severe haemophilia (16 families) and in 45 of the patients with mild or moderate haemophilia (18 families). However, the results were discrepant (FVIII:C by one-stage assay 2-7-fold higher than by two-stage assay) in the other 29 patients with mild or moderate haemophilia (12 other families). For each patient with discrepant FVIII:C results the classification was the same for all other affected members of his family. In some families with haemophilia A the gene defect leads to a discrepancy between the one-stage and two-stage FVIII:C results and may be more widespread than previously recognized.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986726     DOI: 10.1111/j.1365-2141.1994.tb06749.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2008-02-25       Impact factor: 5.157

2.  Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway.

Authors:  M Monaghan; H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2016-03-21       Impact factor: 5.824

3.  Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.

Authors:  Steffen Rosen; Stefan Tiefenbacher; Mary Robinson; Mei Huang; Jaydeep Srimani; Donnie Mackenzie; Terri Christianson; K John Pasi; Savita Rangarajan; Emily Symington; Adam Giermasz; Glenn F Pierce; Benjamin Kim; Stephen J Zoog; Christian Vettermann
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

Review 4.  Factor VIII structure and function.

Authors:  Philip J Fay
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

5.  Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A.

Authors:  Annette E Bowyer; Joost J Van Veen; Anne C Goodeve; Steve Kitchen; Michael Makris
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

6.  Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.

Authors:  M Monaghan; H Wakabayashi; A Griffiths; J Wintermute; P J Fay
Journal:  Thromb Haemost       Date:  2014-06-05       Impact factor: 5.249

7.  Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay.

Authors:  Wilmare Gouws; Elsabie Botha; Adele Visser
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

8.  Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface.

Authors:  Hironao Wakabayashi; Fatbardha Varfaj; Jennifer Deangelis; Philip J Fay
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

9.  Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations.

Authors:  H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2008-12-04       Impact factor: 5.824

10.  A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.

Authors:  Joshua Eubanks; W Hunter Baldwin; Rebecca Markovitz; Ernest T Parker; Courtney Cox; Christine L Kempton; Shannon L Meeks
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.